• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

Medical News Interviews

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Enzalutamide improves overall and progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer

0
  • by karen
  • in AJO · Oncology
  • — 6 Mar, 2014

SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metastatic castration-resistant prostate cancer was asymptomatic or mildly symptomatic and had not been treated with chemotherapy in the phase III PREVAIL study. Dr Tomasz Beer MD, FACP, from Oregon Health & Science University in Portland, USA, presented his group’s findings to the 2014 ASCO Genitourinary Cancers Symposium from 1717 patients randomised to treatment with enzalutamide or placebo. Overall survival was extended by over two months to a median of 32.4 months while progression free survival went up from four to 14 months with the active drug. He discussed the clinical implications with AudioMedica.com.

CONTACT:
Dr. Tomasz Beer MD, FACP
Oregon Health & Science University
Hematology and Medical Oncology,
Portland
3181 S.W. Sam Jackson Park Rd.
Oregon 97239-3098

SOURCE:
Abstract number: LBA1^

LINK:
Web link: http://www.asco.org/sites/www.asco.org/files/gu14_lba1.pdf

Share

Tags: 2014 ASCO Genitourinary Cancers Symposiumandrogen receptor blockade for prostate cancercastration resistant metastatic prostate cancerchemotherapy-naïve metastatic castration-resistant prostate cancerenzalutamide

You may also like...

  • Mario Sznol PD 1 inhibitor nivolumab shows promising activity in metastatic melanoma 21 Sep, 2013
  • Audio Journal of Oncology in Advance – January 15th, 2007 – HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer Audio Journal of Oncology in Advance – January 15th, 2007 – HERA Study Results Confirm Trastuzumab Benefit in HER2 Positive Early Breast Cancer 17 Jan, 2007
  • Oncology Times Broadcast News with the Audio Journal of Oncology – Cancer Related Fatigue Questionnaires Assessed Oncology Times Broadcast News with the Audio Journal of Oncology – Cancer Related Fatigue Questionnaires Assessed 6 Apr, 2009
  • Audio Journal of Oncology in Advance – March 15th, 2008 Audio Journal of Oncology in Advance – March 15th, 2008 16 Mar, 2008

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Previous story Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer risk
  • Next story Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.
  • News

    • Mandeep Mehra MDCOVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
    • Ultrahypofractionated Radiation Just As Effective for Prostate CancerUltrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
    • Paracetamol Poisoning: 12-hour modified acetylcysteine treatment for paracetamol poisoning reduced side effects associated with standard regimen.Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
  • Related interviews

    • Ibrutinib: New Frontline Standard for Chronic…
    • Microbiome Diversity Key To Survival After…
    • New Front Line Standard for Older Patients with…
    • Genomic-led AML Clinical Decision Making Within Seven Days
    • Genomically Targeted Therapy Delays Advanced Breast…
  • Home
  • Oncology
  • AJO
  • Enzalutamide improves overall and progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer

© Copyright 2021 AudioMedica.com. Typegrid Theme by WPBandit.